Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions

Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions

Bavarian Nordic A/S will acquire two oral vaccines from Emergent BioSolutions for a total consideration of up to $380 million, to strengthen its position in the travel vaccines space. The acquisition is expected to help Bavarian Nordic expand its US commercial sales, marketing, and distribution network, as well as increased scale in additional European markets. […]

Visby Medical adds $35m to Series E round for PCR diagnostic technology

Visby Medical adds $35m to Series E round for PCR diagnostic technology

Visby Medical, an American medical diagnostic company, has raised an additional $35 million for its PCR diagnostic technology to take its Series E funding round to over $135 million. The additional investment of $35 million was led by Lightrock. The UK-based private equity platform joined other Series E investors that include John Doerr, ND Capital, […]

Model Medicines, Sanford Burnham Prebys forge AI-driven drug discovery partnership

Model Medicines, Sanford Burnham Prebys forge AI-driven drug discovery partnership

AI drug discovery software company Model Medicines has signed a multi-target collaboration agreement with California-based Sanford Burnham Prebys Medical Discovery Institute for identifying and developing drugs for novel antiviral targets. The collaboration will make use of Model Medicines’ ActivPred AI Drug Discovery Platform, a drug, target, and disease agnostic digital chemistry engine, in conjunction with […]

Thermo Fisher to acquire molecular diagnostic company Mesa Biotech for up to $500m

Thermo Fisher to acquire molecular diagnostic company Mesa Biotech for up to $500m

Thermo Fisher Scientific has agreed to acquire California-based point-of-care molecular diagnostic company Mesa Biotech in a deal worth up to $500 million. The consideration includes nearly $450 million in cash and an additional amount of up to $100 million, which will be subject to Mesa Biotech achieving certain milestones post-acquisition. The molecular diagnostic company has […]

Gilead Sciences announces Veklury EU approval for COVID-19 treatment

Gilead Sciences announces Veklury EU approval for COVID-19 treatment

Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from the European Commission as a treatment for SARS-CoV-2 infection, the virus behind COVID-19. According to the US pharma company, the conditional marketing authorization for Veklury was given in the interest of public health because of the coronavirus pandemic […]

Eiger BioPharmaceuticals doses first patients with Lambda in COVID-19 trial

Eiger BioPharmaceuticals doses first patients with Lambda in COVID-19 trial

Eiger BioPharmaceuticals said that it has dosed the first patients in a phase 2 trial of its hepatitis delta virus drug candidate peginterferon lambda (Lambda) in outpatients at the Stanford University School of Medicine having mild COVID-19. The California-based biopharma company said that nearly 120 patients will be randomly grouped in a 1:1 ratio to […]

CytoAgents, Quotient Sciences to take COVID-19 drug candidate GP1681 into human trials

CytoAgents, Quotient Sciences to take COVID-19 drug candidate GP1681 into human trials

US biotech company CytoAgents has joined forces with CDMO and CRO services provider Quotient Sciences to accelerate the development of its COVID-19 drug candidate GP1681 into human clinical trials for the treatment of cytokine storm. According to the partners, scientific consensus is building that severe illness resulting from COVID-19 and other infectious diseases is triggered by […]

Sinovac Biotech gets approval to begin coronavirus vaccine trial

Sinovac Biotech gets approval to begin coronavirus vaccine trial

Coronavirus vaccine trial : Chinese biopharma company Sinovac Biotech has secured approval to carry out a human clinical trial on an inactivated COVID-19 vaccine candidate, which it had been developing since late January. The company said that its scientists have quickly wrapped up comprehensive preclinical studies in collaboration with some of the top academic research […]